Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
.png)
Anxiety disorders are the most common mental health conditions in the United States — affecting an estimated 40 million adults — yet they remain chronically undertreated. Most people who seek help cycle through SSRIs, therapy, and benzodiazepines. Many find partial relief. Some find none.
Ketamine is showing up as a meaningful alternative, particularly for people whose anxiety hasn't responded to conventional treatment. This article explains the science behind why, breaks down what the evidence shows for specific anxiety disorders, and describes what ketamine therapy actually looks like in practice.
_Reviewed by the clinical team at Isha Health._
First-line treatments for anxiety — SSRIs, SNRIs, and cognitive behavioral therapy (CBT) — work well for a substantial portion of patients. But their limitations are real:
For patients with treatment-resistant anxiety, or those in acute distress who can't wait weeks for relief, these limitations matter enormously. Ketamine works through a completely different mechanism — and that's exactly why it can succeed where other treatments haven't.
Most anxiety medications target the serotonin or GABA systems. Ketamine works primarily on the glutamate system, which plays a more fundamental role in how the brain learns, unlearns, and encodes fear.
Ketamine blocks NMDA receptors — a class of glutamate receptors that are heavily involved in the neural circuits underlying chronic worry, fear conditioning, and threat hypervigilance. Blocking these receptors interrupts the feedback loops that keep anxious thought patterns locked in place, providing a kind of neurological "pause" that allows the brain to reorganize.
Within hours of administration, ketamine triggers a surge in brain-derived neurotrophic factor (BDNF), promoting the growth of new synaptic connections. This is the same mechanism that underlies ketamine's rapid antidepressant effects — and it's directly relevant to anxiety, because the rigid, threat-biased neural patterns that characterize anxiety disorders become more malleable during this window of heightened plasticity.
The glutamate system governs fear extinction — the brain's process for "unlearning" a conditioned fear response. Ketamine's effects on glutamate signaling may directly accelerate fear extinction, making it easier for the brain to release learned anxiety responses that no longer serve a protective function.
Unlike SSRIs, which require weeks to accumulate therapeutic effect, ketamine often produces noticeable anxiety relief within hours of a session. For patients who have been struggling for years, this rapid onset can be genuinely life-changing.
The research base for ketamine in anxiety is growing, though it lags behind the depression literature in terms of large-scale RCTs. Here's what the evidence currently supports:
Generalized Anxiety Disorder (GAD): Multiple studies have documented rapid, significant reductions in GAD symptoms following ketamine administration, with effects appearing within 24 hours and persisting for days to weeks. A 2017 study in Neuropsychopharmacology (Feder et al.) found that a single ketamine infusion produced significant reductions in anxiety symptoms in patients with comorbid depression and anxiety, with effects lasting beyond the infusion itself.
Social Anxiety Disorder: A 2018 randomized controlled trial published in Neuropsychopharmacology specifically examined ketamine for social anxiety disorder and found significant symptom reduction compared to placebo, with rapid onset and a favorable tolerability profile.
OCD: Emerging evidence suggests ketamine may be effective for obsessive-compulsive disorder — a condition notoriously resistant to SSRIs and therapy. A 2013 study in Biological Psychiatry found that a single ketamine infusion produced rapid, significant reductions in OCD symptoms that outlasted the drug's acute effects, suggesting a genuine neurobiological mechanism rather than simple sedation.
Panic Disorder and PTSD-related anxiety: The evidence overlaps here with the broader trauma literature. Ketamine's effects on fear reconsolidation are particularly relevant for anxiety that is rooted in traumatic experience. For more detail on the PTSD-specific evidence, see our ketamine therapy for PTSD guide.
An important honest caveat: most studies to date involve small sample sizes and relatively short follow-up periods. Long-term durability data is still limited. The clinical experience of practitioners working in this space is consistently positive, but this is an evolving field and the research is still catching up to practice.
GAD is characterized by persistent, excessive worry across multiple domains of life — work, health, relationships, finances — that the person experiences as difficult or impossible to control. It's often accompanied by physical symptoms like muscle tension, fatigue, and sleep disruption.
The neural signature of GAD involves chronic overactivation of the amygdala and hyperconnectivity between the amygdala and the default mode network — the brain's "resting state" circuitry that drives rumination. Ketamine's effects on glutamate signaling appear to dampen this hyperconnectivity, reducing the intensity and frequency of worry cycles.
For patients with GAD who haven't responded to SSRIs or SNRIs, ketamine — particularly in the context of KAP with integration therapy — offers a chance to interrupt the worry loop at a neurobiological level while simultaneously building new cognitive and emotional patterns through therapy.
Social anxiety disorder (SAD) involves intense fear of social situations driven by concern about negative evaluation from others. At its core, it's a conditioned fear response — one that has been learned through experience and reinforced over time.
This is where ketamine's effects on fear extinction are most directly relevant. By facilitating the unlearning of conditioned social fear, and by creating a window of heightened neuroplasticity during which new associations can be formed, ketamine can make social situations feel less threatening — sometimes rapidly and durably. The 2018 RCT mentioned above found that patients with SAD showed significant, lasting reduction in symptoms after ketamine, with effects that persisted beyond the acute pharmacological window.
Obsessive-compulsive disorder is one of the most treatment-resistant psychiatric conditions. Standard treatment — SSRIs at high doses plus exposure and response prevention (ERP) therapy — works for roughly 50–60% of patients. For the remainder, options are limited.
Ketamine's mechanism is particularly interesting for OCD: NMDA receptor antagonism may directly interrupt the compulsive thought-action loops that characterize the disorder, while the neuroplasticity effects may make ERP therapy more effective when done in the integration period following ketamine. Early evidence is promising, and for patients who have exhausted standard approaches, KAP represents a meaningful option.
Panic disorder involves recurrent, unexpected panic attacks alongside persistent fear of future attacks and avoidance behaviors. The anticipatory anxiety — the anxiety about having anxiety — is often as debilitating as the attacks themselves.
Ketamine may address panic disorder both through its direct anxiolytic effects and through its capacity to reduce the hypervigilance and interoceptive sensitivity that underlie panic. Integration-focused KAP can additionally help patients develop new relationships with their body's sensations — reducing the catastrophic interpretation of physical arousal that triggers panic spirals.
A significant proportion of people with anxiety also have depression — and vice versa. Ketamine's evidence base in depression is more extensive, and for patients presenting with comorbid anxiety and depression, the combined effect can be substantial. Many patients report that the depressive weight lifting also loosens the grip of anxiety, and some studies suggest ketamine's anxiolytic effects are partially independent of its antidepressant effects.
Isha Health offers ketamine-assisted psychotherapy (KAP) via telemedicine across California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. Here's how the process works:
Intake and evaluation: A thorough clinical assessment establishes your diagnosis, reviews your treatment history, identifies contraindications, and determines whether ketamine is appropriate for your specific presentation.
Preparation: Before your first dosing session, you'll meet with a KAP-trained therapist to set intentions, discuss what to expect, and build the therapeutic foundation that makes integration effective.
Dosing session: Ketamine is administered as a sublingual lozenge (troche) in your home. Sessions run 60–90 minutes. An eye mask, curated music, and a calm environment are standard — the goal is to create conditions for a meaningful inner experience, not to push through anxiety content directly.
Integration: The neuroplasticity window that opens after a dosing session — typically 24–72 hours — is where the most important therapeutic work happens. Integration sessions with your therapist during this window help translate the ketamine experience into lasting changes in how you relate to anxiety.
Ongoing care: Most patients complete an initial series of 3–6 sessions. Some require periodic maintenance. We'll design a plan that fits your life and your goals.
You may be a good candidate for ketamine therapy if:
You may not be a good candidate if you have active psychosis, uncontrolled hypertension, a history of severe manic episodes, or active substance use disorder.
How quickly does ketamine work for anxiety?
Many patients report noticeable reductions in anxiety symptoms within hours to days of their first session. The full therapeutic effect typically builds over an initial series of sessions combined with integration therapy.
Can ketamine make anxiety worse?
The dissociative experience of ketamine can be disorienting, and for some patients this initially increases anxiety during the session itself. This is why preparation, set, and setting matter — and why supervised, structured KAP produces better outcomes than unsupported ketamine use. Our clinical team screens for and manages this risk carefully.
Will I need to stop my SSRI to do ketamine?
In most cases, no. SSRIs are generally compatible with ketamine therapy. We review all medications at intake. The exception is MAOIs, which require discontinuation before treatment.
Is ketamine covered by insurance for anxiety?
Off-label ketamine use is typically not covered by insurance. The therapy component of KAP may be reimbursable depending on your plan. We provide a superbill for out-of-network submission.
How is KAP different from just taking ketamine?
Ketamine alone produces a neuroplasticity window. KAP uses that window therapeutically — with preparation and integration sessions that help you get the most from that window. For anxiety specifically, the integration work is often where the most durable change happens.
Anxiety has a neurobiological architecture — and that architecture can change. Ketamine, particularly in the context of structured KAP, targets anxiety at the level of the glutamate system and synaptic plasticity, offering a mechanism of action that SSRIs and benzodiazepines simply don't have.
For patients who haven't found sufficient relief from conventional approaches, it represents one of the most promising options currently available.
If you're in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, or Washington, we'd be glad to help you figure out if ketamine therapy is right for your anxiety.
Isha Health is a physician-led telehealth practice offering ketamine-assisted psychotherapy for anxiety, depression, PTSD, and other mood disorders across nine states.
